Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature 395, 13-15 (3 September 1998) | doi:10.1038/25595
Open Innovation Challenges
-
Direct Molecular Detection of Proteins and Nucleic Acids
This Challenge is looking for novel approaches to protein and nucleic acid detection. This is an Id...
-
Optimizing Sub-cellular Localization Tags
The Seeker is looking for methods to optimize sub-cellular localization tags for protein expression....
- More Challenges
- Powered by:
nature jobs
Senior Lecturer / Lecturer in Filarial Parasitology
- LSTM
- Liverpool, United Kingdom
Post Doctoral Research Assistant
- University of Bedfordshire
- Bedford, UK
Cancer: Has the smart bomb been defused?
Steven P. Linke1
A goal of cancer research is to develop therapies that can selectively kill tumour cells without adversely affecting normal cells — this is crucial for both the short-term comfort and long-term survival of patients. One such agent is a genetically engineered adenovirus from ONYX Pharmaceuticals, called ONYX-015, which is thought to selectively replicate in (and kill) tumour cells deficient for the p53 tumour-suppressor pathway, having little toxicity to normal cells1,2.
- Steven P. Linke is at the Laboratory of Human Carcinogenesis, National Cancer Institute, National Institutes of Health, 9,000 Rockville Pike, Bethesda, Maryland 20892-4255, USA.
e-mail: Email: slinke@helix.nih.gov
To read this story in full you will need to login or make a payment (see right).
